COVID-19 AND CANCER: SCIENTIFIC AND CLINICAL ASPECTS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-24-2-2022-g.10627Keywords:
COVID-19, malignant neoplasms, risk factors, SARS-CoV-2, vaccines against COVID-19Abstract
There were analyzed scientific publications concerning one of the most important medical and social problems of the 21st century, which afflicted the population of many countries — the COVID-19 outbreak caused by highly mutating and producing new rapidly spreading virulent strains SARS-CoV-2 virus. The issue of the pathogenetic relation between COVID-19 and cancer is considered, and the possible molecular mechanisms determining the predisposition of patients with malignant neoplasms to SARS-CoV-2 infection are discussed. It has been noted that the clinical manifestations of COVID-19 could be different in patients with various forms of malignant neoplasms. In particular, the severe course of the disease in patients with hematological malignancies was emphasized. In addition, the questions related to the effectiveness, safety, and immunogenicity of the most common vaccines against coronavirus is considered based on the multicenter comparative studies in large populations of patients with or without cancer. It was shown that the vaccines can enhance both humoral and cellular antivirus immunity in cancer patients, and that basic precautions and vaccination are the only preventive strategies in the COVID-19 pandemic.
References
Šálek T, Slopovský J, Pörsök Š, et al. COVID-19 and oncological disease. Klin Onkol Spring 2021; 34 (3): 211–9. doi: 10.48095/ccko2021211.
https://phc.org.ua/news/rivni-epidemichnoi-nebezpeki-poshirennya-covid-19-v-ukraini-27.
https://life.pravda.com.ua/health/2022/04/28/248439/.
Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 2020; 395 (10234): 1407–9. doi: 10.1016/S0140-6736(20)30858-8.
Ottaiano A, Scala S, D’Alterio C, et al. Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-CoV-2 infection. Ther Adv Med Oncol 2021; 13: 1–5. doi: 10.1177/17588359211011455
Zhang J, Jiang H, Du K, et al. Pan-cancer analysis of genomic and prognostic characteristics associated with coronavirus disease 2019 regulators. Front Med (Lausanne) 2021; 8: 662460. doi: 10.3389/fmed.2021.662460.
Zhang Y, Mao Q, Li Y, et al. Cancer and COVID-19 susceptibility and severity: a two-sample mendelian randomization and bioinformatic analysis. Front Cell Dev Biol 2022; https://doi.org/10.3389/fcell.2021.759257.
Gao L, Li G-S, Li J-D, et al. Identification of the susceptibility genes for COVID-19 in lung adenocarcinoma with global data and biological computation methods. Comput Struct Biotechnol J 2021; 19: 6229–39. doi: 10.1016/j.csbj.2021.11.026.
Liang X, Chen Y, Fan Y. Bioinformatics approach to identify common gene signatures of patients with coronavirus 2019 and lung adenocarcinoma. Environ Sci Pollut Res Int 2021; 1–19. doi: 10.1007/s11356-021-17321-9.
Hou Y, Zhao J, Martin W, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Medicine 2020; 18 (1): 216. doi: 10.1186/s12916-020-01673-z.
Zong Z, Wei Y, Ren J, et al. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Mol Cancer 2021; 20 (1): 76. doi: 10.1186/s12943-021-01363-1.
Goubran H, Stakiw J, Seghatchian J, et al. SARS-CoV-2 and cancer: the intriguing and informative cross-talk. Transfus Apher Sci 2022; 61 (4): 103488. doi: 10.1016/j.transci.2022.103488.
Iovino L, Thur LA, Gnjatic S, et al. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. J Immunother Cancer 2021; 9 (5): e002392. doi: 10.1136/jitc-2021-002392.
Derosa L, Melenotte C, Griscelli F, et al. The immuno-oncological challenge of COVID-19. Nat Cancer 2020; 1: 946–64. doi: 10.1038/s43018-020-00122-3.
Study suggests blood cancer patients may have higher risk of COVID-19 infection and death. ONCOGENOTES https://www.cancercenter.com/community/blog/2020/10/covid-blood-cancers.
du Plessis M, Fourie C, Riedemann J, et al. Cancer and COVID-19: collectively catastrophic. Cytokine Growth Factor Rev 2022; 63: 78–89. doi: 10.1016/j.cytogfr.2021.10.005.
Russell B, Moss CL, Palmer K, et al. COVID-19 risk factors for cancer patients: a first report with comparator data from COVID-19 negative cancer patients. Cancers (Basel) 2021; 13 (10): 2479. doi: 10.3390/cancers13102479.
Höllein A, Bojko P, Schulz S, et al. Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study. Acta Oncologica 2021; 60: 24–7. https://doi.org/10.1080/0284186X.2020.1863464.
Indini A, Rijavec E, Ghidini M, et al. Coronavirus infection and immune system: an insight of COVID-19 in cancer patients. Crit Rev Oncol Hematol 2020; 153: 103059. doi: 10.1016/j.critrevonc.2020.103059.
Addeo A, Friedlaender A. Cancer and COVID-19: unmasking their ties. Cancer Treat Rev 2020; 88: 102041. doi: 10.1016/j.ctrv.2020.102041.
Nilius-Eliliwi V, Mika T, Baraniskin A, et al. Successful chimeric antigen receptor (CAR) T-cell Treatment in aggressive lymphoma despite coronavirus disease 2019 (CoVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Front Oncol 2021; 11: 706431. doi: 10.3389/fonc.2021.706431.
Madduri D, Parekh S, Campbell TB, et al. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep 2021; 15 (1): 90. doi: 10.1186/s13256-020-02598-0.
Kulkarni AA, Wilson G, Fujioka N, Pate MR. Mortality from COVID-19 in patients with lung cancer. J Cancer Metastasis Treatment 2021; 7: covidwho-1417393. https://jcmtjournal.com/article/view/4118.
Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020; 31 (10): 1386–96. doi: 10.1016/j.annonc.2020.06.007.
Lemos AEG, Silva GR, Gimba ERP, Matos ADR. Susceptibility of lung cancer patients to COVID-19: A review of the pandemic data from multiple nationalities. Thorac Cancer. 2021; 12 (20): 2637–47. doi: 10.1111/1759-7714.14067.
Passaro A, Bestvina C, Velez Velez M, et al. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021; 9 (3): e002266. doi: 10.1136/jitc-2020-002266.
Fuentes-Antrás J, Manzano A, Marquina G, et al. A snapshot of COVID-19 infection in patients with solid tumors. Int J Cancer 2020; 148 (10): 2389–97. doi: 10.1002/ijc.33420.
Vuagnat P, Frelaut M, Ramtohul T, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res 2020; 22 (1): 55. doi: 10.1186/s13058-020-01293-8.
Alagoz O, Lowry KP, Kurian AW, et al. Impact of the COVID-19 pandemic on breast cancer mortality in the US: estimates from collaborative simulation modeling. J Natl Cancer Inst 2021; 113 (11): 1484–94. doi: 10.1093/jnci/djab097.
Lasagna A, Zuccaro V, Ferraris E, et al. COVID-19 and breast cancer: may the microbiome be the issue? Future Oncol 2021; 17 (2): 123–6. doi: 10.2217/fon-2020-0764.
Purut YE, Giray B, Gurbuz E. Effect of the coronavirus pandemic on tumor markers. J Med Virol 2021; 93 (9): 5405–8. doi: 10.1002/jmv.27057.
Francescangeli F, De Angelis ML, Zeuner A. COVID-19: a potential driver of immune-mediated breast cancer recurrence? Breast Cancer Research 2020; 22 (1): 117. doi: 10.1186/s13058-020-01360-0.
Chakravarty D, Ratnani P, Sobotka S, et al. Increased hospitalization and mortality from covid-19 in prostate cancer patients. Cancers (Basel) 2021; 13 (7): 1630. doi: 10.3390/cancers13071630.
Hisham F. Bahmad & Wassim Abou-Kheir. Crosstalk between COVID-19 and prostate cancer. Prostate Cancer Prostatic Dis 2020; 23 (4): 561–3. doi: 10.1038/s41391-020-0262-y.
Schmidt AL, Tucker MD, Bakouny Z, et al. Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19. JAMA Netw Open 2021; 4 (11): e2134330. doi:10.1001/jamanetworkopen.2021.34330.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (2): 271–280e278. doi: 10.1016/j.cell.2020.02.052.
Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 2020; 34 (2): 339–43. doi: 10.23812/Editorial-Conti-3.
Kloc M, Ghobrial RM, Kubiak JZ. The role of genetic sex and mitochondria in response to COVID-19 infection. Int. Arch. Allergy Immunol 2020; 181 (8): 629–34. doi: 10.1159/000508560.
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16(10), 626–8. doi: 10.1038/nri.2016.90.
Chakravarty D, Nair SS, Hammouda N, et al. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol 2020; 3 (1): 374. doi: 10.1038/s42003-020-1088-9.
Ding T, Zhang J, Wang T, et al. Potential influence of menstrual status and sex hormones on female SARS-CoV-2 infection: a cross-sectional study from multicentre in Wuhan, China. Clin Infect Dis 2020; 72 (9): e240-e248. doi: 10.1093/cid/ciaa1022.
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395 (10241): 1907–18. doi: 10.1016/S0140-6736(20)31187-9.
Vemuri R, Sylvia KE, Klein SL, et al. The microgenderome revealed sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol 2019; 41 (2): 265–75. doi: 10.1007/s00281-018-0716-7.
Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J Natl Cancer Inst 2016; 108 (8): djw029. doi: 10.1093/jnci/djw029.
Parida S, Sharma D. The microbiome–estrogen connection and breast cancer risk. Cells 2019; 8 (12): 1642. doi: 10.3390/cells8121642.
Pollet RM, D’Agostino EH, Walton WG, et al. An atlas of β-glucuronidases in the human intestinal microbiome. Structure 2017; 25 (7): 967–77. doi: 10.1016/j.str.2017.05.003.
Luu TH, Michel C, Bard JM, et al. Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. Nutr Cancer 2017; 69 (2): 267–75. doi: 10.1080/01635581.2017.1263750.
Parida S, Sharma D. The power of small changes: comprehensive analyses of microbial dysbiosis in breast cancer. Biochim Biophys Acta Rev Cancer 2019; 1871 (2): 392–405. doi: 10.1016/j.bbcan.2019.04.001.
Thierry AR, Pastor B, Pisareva E, et al. Association of COVID-19 lockdown with the tumor burden in patients with newly diagnosed metastatic colorectal cancer. JAMA Netw Open 2021; 4 (9): e2124483. doi:10.1001/jamanetworkopen.2021.24483
COVID-19: what the brain tumor community needs to know. National Brain Tumor Society. https://braintumor.org/support-services/toolkit/covid-19/.
Deligiorgi MV, Siasos G, Vakkas L, Trafalis DT. Charting the unknown association of COVID-19 with thyroid cancer, focusing on differentiated thyroid cancer: a call for caution. Cancers (Basel) 2021; 13 (22): 5785. doi: 10.3390/cancers13225785.
Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome — an analysis of the LEOSS registry. Ann Hematol 2021; 100: 383–93. doi: 10.1007/s00277-020-04328-4.
Pinato DJ, Patel M, Scotti L, et al. time-dependent covid-19 mortality in patients with canceran updated analysis of the onCOVID registry. JAMA Oncol 2022; 8 (1): 114–22. doi:10.1001/jamaoncol.2021.6199.
Fendler A, de Vries EGE, Geurtsvan Kessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature Reviews Clinical Oncology 2022; 19 (6): 385–401. doi: 10.1038/s41571-022-00610-8.
Sayed S. COVID-19 and Malignancy: Exploration of the possible genetic and epigenetic interlinks and overview of the vaccination scenario. Cancer Treatment and Research Communications 2021; 28: 100425. doi: 10.1016/j.ctarc.2021.100425.
Cortés A, Casado JL, Longo F, et al. Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. Eur J Cancer 2022; 166: 229–39. doi: 10.1016/j.ejca.2022.02.017.
Song Q, Bates B, Shao YR, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative. J Clin Oncol 2022; 40 (13): 1414–27. doi: 10.1200/JCO.21.02419.
Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US Nationwide Veterans Affairs Study. JAMA Oncol 2022; 8 (2): 281–6. doi: 10.1001/jamaoncol.2021.5771.
Prasad RN, Patel M, Palmer JD. COVID-19 booster vaccine equity for patients with cancer. Adv Radiat Oncol 2022; 7 (5): 100939. doi: 10.1016/j.adro.2022.100939.
https://life.pravda.com.ua/health/2022/01/
/247028/.
Shun CLK. A causal (regression) analysis for cancer formation under a corresponding virus attack. Int J Sci Academ Research 2021; 02 (07): 1846–8. https://www.researchgate.net/publication/352466535.
Rajan S, Akhtar N, Sharma S, et al. COVID-19 vaccination for cancer patients: Evidence, priority, and practice. Vaccine 2021; 39 (36): 5075–7. doi: 10.1016/j.vaccine.2021.07.063.
Kanjanapan Y, Cavic G, Almonte A, et al. COVID-19 vaccine response in patients on cancer therapy — evidence from australian data. https://onlinelibrary.wiley.com/doi/10.1111/imj.26_15766.
Waldhorn I, Holland R, Goshen-Lago T, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov 2021; 11 (10): 2430–5. https://doi.org/10.1158/2159-8290.CD-21-1072.
Guimaraes de Sousa L, McGrail DJ, Li K, et al. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 2022; 10 (3): e004371. doi: 10.1136/jitc-2021-004371.
Heudel P, Favier B, Assaad S, et al. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. Ann oncol 2021; 32 (11): 1443–4. doi: 10.1016/j.annonc.2021.07.012.
Shulman RM, Weinberg DS, Ross EA, et al. Adverse events reported by patients with cancer after administration of a 2-Dose mRNA COVID-19 vaccine. https://doi.org/10.6004/jnccn.2021.7113.
